Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.
Scope of the Report:
This report focuses on the Biosimilar Drug in China market. This report categorizes the market based on manufacturers, type and application.
Market Segment by Manufacturers, this report covers
- CP Guojian
- Henlius Biotech
- Eli Lilly
- Changchun High Tech
Market Segment by Type, covers
Market Segment by Applications, can be divided into
- Ankylosing Spondylitis
- Rheumatoid Arthrtis
There are 11 Chapters to deeply display the China Biosimilar Drug market.
Chapter 1, to describe Biosimilar Drug Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Biosimilar Drug, with sales, revenue, and price of Biosimilar Drug, in 2015 and 2016;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2015 and 2016;
Chapter 4 and 5, to show the market of Biosimilar Drug by type and application, with sales market share and growth rate by type, application, from 2011 to 2016;
Chapter 6, Biosimilar Drug market forecast, by type and application, with sales and revenue, from 2016 to 2021;
Chapter 7, to analyze the Biosimilar Drug market development potential except China, covering China, Southeast Asia, India, Latin America etc.
Chapter 8, 9, 10 and 11, to describe sales channel, distributors, traders, dealers, market effect factors, appendix and data source.